Search
Spironolactone
go.drugbank.com/drugs/DB00421ApprovedInvestigational[A178135, A261025] Spironolactone was developed in 1957, marketed in 1959, and approved by the FDA on January 21, 1960.[A178243] … Spironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists.
Anti-inhibitor coagulant complex
go.drugbank.com/drugs/DB13151ApprovedInvestigationalIt is used to control bleeding in hemophilia A and B patients with inhibitors. … Anti-inhibitor coagulant complex, also known as FEIBA (factor eight inhibitor bypassing activity), contains several proteins involved in the prothrombinase complex.
Foreskin keratinocyte (neonatal)
go.drugbank.com/drugs/DB10772ApprovedThe defining moment in skin culture was in 1975 when Rheinwald and Green successfully grew human keratinocytes on lethally irradiated murine fibroblasts. … Skin, the largest organ of the human body, plays the main role in protecting the body from mechanical damage. It is composed of epidermal, dermal and hypodermal layers.
Islatravir
go.drugbank.com/drugs/DB15653ApprovedInvestigationalIslatravir is a first-in-class, highly potent nucleoside reverse transcriptase translocation inhibitor (NRTTI) used in combination therapy for the treatment of HIV-1 infection. … [L56141] This formulation represents a significant advance in long-acting oral therapy due to islatravir's exceptionally long intracellular half-life, which allows for extremely low dosing.
Prasterone
go.drugbank.com/drugs/DB01708ApprovedInvestigationalNutraceuticalPrasterone, also known as dehydroepiandrosterone (DHEA) is a major C19 steroid produced by the adrenal cortex. It is also produced in small quantities in the testis and the ovary. … In Canada, a prescription is required to buy DHEA.
Synonyms: 3β-hydroxyandrost-5-en-17-one, 3beta-hydroxyandrost-5-en-17-oneNipocalimab
go.drugbank.com/drugs/DB16257ApprovedInvestigational[L64042] This reduction in autoantibodies underlies its therapeutic effect across autoantibody-driven conditions.[L64042] It is administered by intravenous infusion. … [L64042] Nipocalimab-aahu was first approved by the FDA in April 2025 for generalized myasthenia gravis.
Atogepant
go.drugbank.com/drugs/DB16098ApprovedInvestigationalnovel in that it is the first and only oral CGRP antagonist approved for preventative use in migraine. … [L38814] In December 2022, atogepant received Health Canada approval for the prevention of episodic migraine in adults.
Escitalopram
go.drugbank.com/drugs/DB01175ApprovedInvestigational[A185420] It is used to restore serotonergic function in the treatment of depression and anxiety. … escitalopram exerts the highest degree of selectivity for the serotonin transporter (SERT) relative to other off-targets which may explain its lower rates of adverse effects as compared to other agents in
Products: Escitalopram-GN 10 mg Filmtabletten, Escitalopram-GN 20 mg FilmtablettenMacimorelin
go.drugbank.com/drugs/DB13074ApprovedGrowth hormone (GH) is classically linked with linear growth during childhood. … In clinical studies involving healthy subjects, macimorelin stimulated GH release in a dose-dependent manner with good tolerability [A31481].
Sucralfate
go.drugbank.com/drugs/DB00364ApprovedInvestigationalIt is sold under many brands and is available in both tablet and suspension forms. It was approved by the FDA 1982 in tablet form, and in 1994 for the suspension form [L6073, L6076]. … , peptic ulcer disease, stress ulcer, in addition to dyspepsia [A177655].